Qualigen Therapeutics (QLGN) Competitors $4.18 +0.11 (+2.70%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends QLGN vs. CLDI, TXMD, CSCI, ACXP, APLM, CLRB, BCLI, TSBX, BLRX, and JAGXShould you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Calidi Biotherapeutics (CLDI), TherapeuticsMD (TXMD), COSCIENS Biopharma (CSCI), Acurx Pharmaceuticals (ACXP), Apollomics (APLM), Cellectar Biosciences (CLRB), Brainstorm Cell Therapeutics (BCLI), Turnstone Biologics (TSBX), BioLineRx (BLRX), and Jaguar Health (JAGX). These companies are all part of the "pharmaceutical products" industry. Qualigen Therapeutics vs. Calidi Biotherapeutics TherapeuticsMD COSCIENS Biopharma Acurx Pharmaceuticals Apollomics Cellectar Biosciences Brainstorm Cell Therapeutics Turnstone Biologics BioLineRx Jaguar Health Calidi Biotherapeutics (NYSE:CLDI) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment. Do institutionals & insiders have more ownership in CLDI or QLGN? 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher valuation & earnings, CLDI or QLGN? Qualigen Therapeutics has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi Biotherapeutics$50K445.06-$29.22MN/AN/AQualigen Therapeutics$4.98M0.62-$13.42MN/AN/A Does the MarketBeat Community believe in CLDI or QLGN? Qualigen Therapeutics received 7 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformCalidi BiotherapeuticsN/AN/AQualigen TherapeuticsOutperform Votes787.50% Underperform Votes112.50% Do analysts rate CLDI or QLGN? Calidi Biotherapeutics presently has a consensus target price of $16.67, indicating a potential upside of 1,881.77%. Given Calidi Biotherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Calidi Biotherapeutics is more favorable than Qualigen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Qualigen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CLDI or QLGN more profitable? Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% Qualigen Therapeutics N/A N/A -424.18% Which has more risk & volatility, CLDI or QLGN? Calidi Biotherapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of -0.69, indicating that its share price is 169% less volatile than the S&P 500. Does the media refer more to CLDI or QLGN? In the previous week, Calidi Biotherapeutics' average media sentiment score of 0.16 beat Qualigen Therapeutics' score of 0.00 indicating that Calidi Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Calidi Biotherapeutics Neutral Qualigen Therapeutics Neutral SummaryCalidi Biotherapeutics beats Qualigen Therapeutics on 9 of the 12 factors compared between the two stocks. Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QLGN vs. The Competition Export to ExcelMetricQualigen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.10M$6.56B$5.39B$9.14BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A9.7988.1017.53Price / Sales0.62331.481,285.4080.11Price / CashN/A22.6336.6032.90Price / Book-0.215.064.954.67Net Income-$13.42M$154.90M$117.96M$224.69M7 Day Performance3.46%2.59%2.49%3.32%1 Month Performance7.44%1.50%3.44%5.36%1 Year Performance-83.30%5.43%27.06%22.59% Qualigen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QLGNQualigen TherapeuticsN/A$4.18+2.7%N/A-83.8%$3.09M$4.98M0.0050CLDICalidi Biotherapeutics3.0568 of 5 stars$0.92+0.4%$16.67+1,714.0%N/A$12.02M$50,000.000.0038TXMDTherapeuticsMD0.5973 of 5 stars$1.04-5.5%N/A-52.5%$11.99M$1.60M0.00420CSCICOSCIENS BiopharmaN/A$3.18-6.5%N/AN/A$11.95M$7.60M-0.2720Gap UpACXPAcurx Pharmaceuticals3.033 of 5 stars$0.70-13.4%$12.00+1,614.3%-76.1%$11.83MN/A-0.643Short Interest ↓APLMApollomics2.3923 of 5 stars$10.85+2.9%$200.00+1,743.3%-89.3%$11.79M$1.22M0.0045CLRBCellectar Biosciences2.8355 of 5 stars$0.28-0.2%$17.67+6,169.2%-93.0%$11.63MN/A-0.1610Analyst ForecastHigh Trading VolumeBCLIBrainstorm Cell Therapeutics4.2346 of 5 stars$2.02flat$30.00+1,385.1%-55.1%$11.52MN/A-0.4240Analyst UpgradeNews CoverageGap UpTSBXTurnstone Biologics3.0688 of 5 stars$0.48-0.2%$2.13+343.6%-77.0%$11.08M$19.31M-0.1582News CoverageBLRXBioLineRx2.9691 of 5 stars$0.14-3.8%$9.00+6,450.2%-92.5%$10.98M$21.99M-0.6240Analyst ForecastStock SplitNews CoverageGap UpJAGXJaguar Health0.5404 of 5 stars$0.93-7.4%N/A-86.1%$10.93M$10.48M0.0050 Related Companies and Tools Related Companies CLDI Competitors TXMD Competitors CSCI Competitors ACXP Competitors APLM Competitors CLRB Competitors BCLI Competitors TSBX Competitors BLRX Competitors JAGX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QLGN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
